🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the infection, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise globally, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on findings released by a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which involves two antibiotics. The research included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to license and sell the drug in many developing nations.

Medical professionals on the front lines have shared positive views. Having a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is deemed vital to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.